Term
|
Definition
|
|
Term
| Peak Action of Lispro/Aspart |
|
Definition
|
|
Term
| Effective Duration of Lispro/Aspart |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Peak action of Regular insulin |
|
Definition
|
|
Term
| Effective duration of Regular insulin |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Effective duration of NPH/Lente |
|
Definition
|
|
Term
| Onset of Lantus/Ultralente |
|
Definition
|
|
Term
| Peak action of Lantus/Ultralente |
|
Definition
|
|
Term
| Effective duration of Lantus/Ultralente |
|
Definition
|
|
Term
| very rapid acting insulin |
|
Definition
|
|
Term
|
Definition
|
|
Term
| intermediate acting insulin |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| 12 units of insulin, call MD |
|
|
Term
| order of meds given to hypoglycemic pt |
|
Definition
1. glucose granules
2. glucose tablet
3. OJ
4. candy
5. glycagon injection |
|
|
Term
|
Definition
| stimulate insulin release from pancreatic B cells |
|
|
Term
|
Definition
| Chlorpropamide (Diabinese), Glyburide (Glynase/Micronase), Glipizide (Glucotrol) |
|
|
Term
| dosage of Chlorpropamide/diabinese |
|
Definition
| 250 mg/day, max dose 500 mg/day |
|
|
Term
| SE of Chlorpropamide/diabinese |
|
Definition
|
|
Term
| DOA of Chlorpropamide/diabinese |
|
Definition
|
|
Term
| Contraindications of Chlorpropamide/diabinese |
|
Definition
|
|
Term
| dosage of glyburide/glynase/micronase |
|
Definition
| starting dose 2.5 mg/day, average maintenance dose 5-10 mg/day, max dose 10 mg/day |
|
|
Term
| DOA of glyburide/glynase/micronase |
|
Definition
|
|
Term
| Contraindications of glyburide/glynase/micronase |
|
Definition
| cirrhosis (b/c it is metabolized in the liver), sulfa allergy, DKA |
|
|
Term
| dosage of glimepiride (amaryl) |
|
Definition
| starting dose: 1 mg/ day, max dose 8 mg/day |
|
|
Term
| DOA of glimepiride (amaryl) |
|
Definition
|
|
Term
| SE of glimepiride (amaryl) |
|
Definition
|
|
Term
| contraindications of glimepiride (amaryl) |
|
Definition
| alcoholism, sulfa allergy |
|
|
Term
| pt. education for glimepiride (amaryl) |
|
Definition
| electrolytes need to be done with every visit |
|
|
Term
| glipizide/ glucotrol dosage |
|
Definition
| 5-15 mg in the morning, max dose 15/mg/dose |
|
|
Term
| SE of glipizide/ glucotrol |
|
Definition
|
|
Term
| contraindications of glipizide/ glucotrol |
|
Definition
|
|
Term
| pt. education for glipizide/ glucotrol |
|
Definition
do not chew, crush, or cut this med
do CBC, LFTs, renal fxn, LDH, alkaline phosphate tests on a regular basis |
|
|
Term
|
Definition
|
|
Term
|
Definition
| most useful in DM pts. who are obese and have increased insulin levels |
|
|
Term
|
Definition
| 500 mg TID with meals, max dose 2000 mg |
|
|
Term
|
Definition
|
|
Term
|
Definition
| lactic acidosis, GI symptoms |
|
|
Term
| contraindications of metformin |
|
Definition
| serum creatinine greater than or equal to 1.5 mg/dl, alcoholism, hepatic insufficiency |
|
|
Term
|
Definition
| primary action is on the liver reducing hepatic gluconeogenesis |
|
|
Term
|
Definition
|
|
Term
| dosage of pioglitazone/actos |
|
Definition
| 15-45 mg/day, do NOT take with food |
|
|
Term
| DOA of pioglitazone/actos |
|
Definition
|
|
Term
|
Definition
| dec. bone density, ovulation in post menopausal women, peripheral edema |
|
|
Term
| contraindications of pioglitazone/actos |
|
Definition
| NY AHA class III or IV cardiac status, active liver ds, ALT levels greater than 2.5x upper limits of normal |
|
|
Term
| pt. education for pioglitazone/actos |
|
Definition
| husband should get vasectomy |
|
|
Term
| MOA of pioglitazone/actos |
|
Definition
| sensitizes peripheral tissue to insulin |
|
|
Term
| dosage of acarbose/precose |
|
Definition
| starting dose 50 mg BID, then increase to 100 mg TID, take with 1st mouthful of food |
|
|
Term
|
Definition
| GI discomfort, flatulence, diarrhea |
|
|
Term
| contraindications of acarbose/precose |
|
Definition
| colonic ulcers, malabsorption syndrome, intestinal ds, cirrhosis |
|
|
Term
|
Definition
| competitively inhibits alpha-glucosidase enzymes in the GI tract that digest starch and sucrose |
|
|
Term
| alpha-glucosidase inhibitors |
|
Definition
|
|
